<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116010">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01932268</url>
  </required_header>
  <id_info>
    <org_study_id>Colchicine_RFP 2011_1</org_study_id>
    <nct_id>NCT01932268</nct_id>
  </id_info>
  <brief_title>A Pilot Study for Pharmacokinetic Parameter of Colchicine in Patient Taking Rifampin</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the colchicine concentration before and after the
      administration of rifampicin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>a change of the colchicine concentration from baseline at 1,2,4,8,24 hours after Rifampicin administration</measure>
    <time_frame>the colchicine concentration of baseline(C0) and at 1(C1),2(C2),4(C4),8(C8),24(C24) hours after Rifampicin administration</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Rifampicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>experimentally check a change of the colchicine concentration from baseline at 1,2,4,8,24 hours after taking Rifampicin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifampicin</intervention_name>
    <description>single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration</description>
    <arm_group_label>Rifampicin</arm_group_label>
    <other_name>Rifampin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  from 18yrs to 80yrs , man and women

          -  the patient who are taking rifampicine over 2weeks

          -  the patient sign on the concent form

        Exclusion Criteria:

          -  the patient have experience to take medication that have an effect on renal function

          -  the patient have hypersensitivity to colchicine

          -  At least, the average level of two separate blood pressure ( 2min interval ) shows
             that SBP &lt;= 100 mmHg or &gt;=160 mmHg and DBP &lt;=60 mmHg &gt;=100 mmHg, or Heart rate &lt; 40
             beats/min or &gt; 90 beats/min

          -  uncontrolled hypertension

          -  serum albumin &lt; 3.5, &gt; 5 g/dL

          -  acute hepatitis or the level of AST or ALT is over 2times of normal range or the
             level of bilirubin is over 2.0 mg/dL

          -  the patient who have gastro-intestinal disease ( ex, crohn's disease, acute or
             chronic pancreatitis, ulcer )or who have the surgical history of gastrointestine.

          -  the patient who should take azathioprine, mercaptopurine, cyclophosphamide, Losartan,
             benzbromarone,fenofibrate,furosemide ,probenecid

          -  the patient who had taken part in the other study within 3months

          -  the patient who had gotten blood transfusion

          -  pregnant, breast feeding
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 26, 2013</lastchanged_date>
  <firstreceived_date>December 7, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colchicine</mesh_term>
    <mesh_term>Rifampin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
